DCM
TEVA icon

Driehaus Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Driehaus Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-7,500
Closed -$25K – 599
2016
Q2 		$25K Buy
+7,500
New +$399K ﹤0.01% 534

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Driehaus Capital Management's TEVA Position: Q2 2025 in Review

Driehaus Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 18,631 shares — an estimated $286K sold.

Driehaus Capital Management first reported a position in TEVA in Q1 2014 and held it in 11 quarters. The position peaked at $65.8M in Q4 2024. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Driehaus Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Driehaus Capital Management sold 18,631 Teva Pharmaceuticals shares in Q2 2025, an estimated $286K.
  • Driehaus Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 11 quarters.
  • Driehaus Capital Management's Teva Pharmaceuticals position peaked at $65.8M in Q4 2024.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Driehaus Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.